YEAR-END REPORT 2014

The full year 2014 and the fourth quarter in brief

  · Net sales amounted to MSEK 30.1 (47.0), whereof the fourth quarter MSEK 8.1
(9.7)
  · Net loss for the group was MSEK 59.3 (22.1), whereof the fourth quarter MSEK
21.8 (3.3)
  · Loss per share was SEK 0.09 (0.04), whereof the fourth quarter SEK 0.03
(0.01)
  · Cash flow from operating activities was MSEK -46.3 (-33.4), whereof the
fourth quarter MSEK -10.7 (-7.9)
  · Cash and cash equivalents and other short-term investments totaled MSEK 51.6
(22.8) at the end of the period
  · The marketing company Karo Pharma was established during the fourth quarter
  · Continued investment in the ERbeta cancer project for advancement towards
the clinic
  · Pfizer has taken over development of the RORgamma project, which means that
the project has taken a step further into a new phase

Significant events after the end of the reporting period

  · On February 4, Anders Lönner was appointed Executive Chairman of the Board
and Maria Sjöberg CEO after Per Bengtsson

Conference call / audiocast today at 11.00 a.m. CET
A presentation of the report (in Swedish) will take place today 11.00 a.m. The
presentation and slides are available through the corporate website
http://www.karobio.se/ or by telephone +468 566 426 94. Questions may be
submitted over the internet or by telephone.

For further information, please contact
Maria Sjöberg, CEO
Telephone: +46 8 608 6024 or 076 – 263 2875
E-mail: maria.sjoberg@karobio.se
Henrik Palm, CFO
Telephone: +46 8 608 6076 or +46 70 540 40 14
E-mail: henrik.palm@karobio.se

Karo Bio AB (publ)
Novum
141 57 Huddinge
Sweden
Telephone: +46 8 608 60 00
Corp.reg.nr. 556309-3359
Website: www.karobio.com

The information in this report is such that Karo Bio is required to disclose
under the Swedish Securities Market Act. The information was disclosed on
February 13, 2015 at 8.30 a.m. CET.